ArticleFrontiers in cardiovascular medicine2025
The value of sST2 in risk stratification and short-term prognosis of acute pulmonary embolism: a pilot study focusing on intermediate-risk subgroups.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intermediate-risk acute pulmonary embolism (APE) represents a heterogeneous group that is temporarily hemodynamically stable and still has a high mortality. The aim of this study was to assess the predictive value of soluble growth stimulation expressed gene 2 (sST2) in risk stratification and short-term prognosis in this group. Methods: This retrospective observational study included 128 patients with intermediate-risk APE between February 2020 to November 2023. Univariate or multivariate analysis were carried out for exploring the associations of sST2 with risk stratification and adverse event. Univariate logistic regression analysis and characteristic curve (ROC) were performed. Results: Compared with the intermediate-low risk group, higher sST2 level (25.8 ng/ml vs. 11.5 ng/ml, Conclusions: sST2 is associated with risk stratification and poor short-term prognosis for intermediate-risk APE, and it is a promising new biomarker that may contribute to further stratification for intermediate-risk subgroups and identification of individuals with a propensity to develop adverse events during hospitalization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.